NCT00734565

Safety and Reactogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b

A Phase I, Single-arm, Single-center Study to Investigate Safety and Reactogenicity of Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b in Healthy Children Aged 16 - 20 Months and Infants Aged 2 - 4 Months

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Novartis Vaccines · Industry
• Sex: All
• Age: 2 Months – 20 Months
• Healthy volunteers: Accepted

Summary

This study will investigate safety and reactogenicity of a monovalent conjugated vaccine against Haemophilus influenzae type b in healthy children

Conditions

• Haemophilus Influenzae Type b

Interventions

Type	Name	Description
BIOLOGICAL	Haemophilus influenzae type b	1 dose monovalent conjugated vaccine against Haemophilus influenzae type b in children aged 16 - 20 months and infants aged 2 - 4 months

Timeline

• Start date: 2008-07-01
• Primary completion: 2008-10-01
• Completion: 2008-10-01
• First posted: 2008-08-14
• Last updated: 2012-02-08

Locations

1 site across 1 country: China